Partnership to enrich drug patent and market intelligence content in the AdisInsight<\/em> platform<\/strong><\/p>\n<\/blockquote>\n Established in 2005, DrugPatentWatch has served large and small biopharmaceutical interests in more than 65 countries. The DrugPatentWatch platform provides rapid access to actionable business intelligence, helping biopharmaceutical stakeholders make better decisions.<\/p>\n \u201cWorking with Adis allows us to distribute our information in a context that will help biotechnology and pharmaceutical companies make better decisions and improve the quality of their portfolio management decisions. Payers can also improve their budgeting, and investors can improve their forecasting of future revenue events,\u201d says Dr. Yali Friedman, Chief Executive of DrugPatentWatch. \u201cThe team at Adis was a pleasure to work with. Their enthusiasm and focus on improving client outcomes was evident throughout the integration. It is also important to work with a partner that shares our commitment to providing current, actionable, and reliable content. The AdisInsight<\/em> platform is unparalleled and we are proud to be working with them to deliver an even more valuable service to their customers.\u201d<\/p>\n Jeff Southwood, Product Development Director for AdisInsight, says: \u201cHaving worked very closely with customers in this space for many years, we know what makes their day-to-day work challenging. One of the major struggles our users face is that they have to rely very heavily on patent attorneys or IP specialists to assess patent protection because of the expertise required to find patents in patent-specific databases and to understand and interpret these complex documents. This can be a time-consuming and costly process. Our goal in developing AdisInsight Patents was to make drug-centric patent information accessible to any user by using familiar search terms and at-a-glance summaries.\u201d<\/p>\n Helping drug companies find new commercial opportunities<\/strong><\/p>\n The integration of DrugPatentWatch\u2019s global patent intelligence into the AdisInsight<\/em> platform helps users make better decisions with accurate, interlinked narratives about drug development. The combination of patent and market entry information with AdisInsight’s <\/em>strong base will help drug companies and other biopharmaceutical stakeholders improve their decision-making processes and identify new commercial opportunities.<\/strong><\/p>\n DrugPatentWatch<\/strong> is provider of global business intelligence on biologic and small-molecule drugs, dedicated to helping clients make better decisions. Critical information on global drug patents is incorporated with litigation intelligence, drug prices, and historic sales figures to help users discover commercial opportunities and forecast future revenue events. Since 2005 DrugPatentWatch has served hundreds of large and small companies in more than 65 countries. DrugPatentWatch founder and Chief Executive Yali Friedman, Ph.D. was named one of the “100 most influential people in biotechnology” by Scientific American<\/em>. Visit https:\/\/www.DrugPatentWatch.com<\/a> and contact admin@DrugPatentWatch.com<\/a> .<\/p>\n","protected":false},"excerpt":{"rendered":" DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis\u2019 […]<\/p>\n","protected":false},"author":1,"featured_media":4227,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10,6],"tags":[],"class_list":["post-4690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights","category-update"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/4690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=4690"}],"version-history":[{"count":0,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/4690\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/4227"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=4690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=4690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=4690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"AdisInsight](\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2019\/04\/adisinsight-patents_400px-228x300.png\")
![\"Make](\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2019\/01\/DrugPatentWatch-Make-Better-Decisions_sq-150x150.jpg\")